In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 3019-3031

  Chauhan, Dharminder ^a   Ray, Arghya ^a   Viktorsson, Kristina ^b   Spira, Jack ^c   Paba Prada, Claudia ^a   Munshi, Nikhil ^a   Richardson, Paul ^a   Lewensohn, Rolf ^b   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; CYTOCHROME C; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; MELPHALAN FLUFENAMIDE; MICROSOMAL AMINOPEPTIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CROSS RESISTANCE; CYTOKINE RELEASE; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOXICITY; HUMAN; HUMAN TISSUE; IC 50; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; MELPHALAN; MICE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PHENYLALANINE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878968738     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3752     Document Type: Article

References (47)

1. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res 2011;17:1225-33.
2. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011;86:1-15.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7. (Pubitemid 26240110)
4. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-36. (Pubitemid 46638847)
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83. (Pubitemid 36532313)
6. Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia 2013;27:695-701.
7. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-44. (Pubitemid 46638848)
8. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767-72. (Pubitemid 46482069)
9. Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: an individual patient data meta-analysis of six randomized trials. Haematologica 2013;98:87-94.
10. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-66.
11. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41.
12. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18. (Pubitemid 47516593)
13. Rajkumar SV. Optimising bortezomib in newly diagnosed multiple myeloma. Lancet Oncol 2010;11:909-10.
14. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119:3003-15.
15. Gullbo J, Wallinder C, Tullberg M, Lovborg H, Ehrsson H, Lewensohn R, et al. Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2. Mol Cancer Ther 2003;2:1331-9.
16. Gullbo J, Lindhagen E, Bashir-Hassan S, Tullberg M, Ehrsson H, Lewensohn R, et al. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drugs 2004;22:411-20. (Pubitemid 39619817)
17. Wickstrom M, Johnsen JI, Ponthan F, Segerstrom L, Sveinbjornsson B, Lindskog M, et al. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther 2007;6:2409-17. (Pubitemid 47480406)
18. Wickstrom M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 2011;102:501-8.
19. Wickstrom M, Viktorsson K, Lundholm L, Aesoy R, Nygren H, Sooman L, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol 2010;79:1281-90.
20. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
21. Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 1992;357:420-2.
22. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19. (Pubitemid 41579835)
23. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000. (Pubitemid 34984425)
24. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012;22:345-58.
25. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010;115:834-45.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
27. Gullbo J, Dhar S, Luthman K, Ehrsson H, Lewensohn R, Nygren P, et al. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L- fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L- fluorophenylalanine ethyl ester): comparison with melphalan. Anticancer Drugs 2003;14:617-24. (Pubitemid 37297261)
28. Gullbo J, Tullberg M, Vabeno J, Ehrsson H, Lewensohn R, Nygren P, et al. Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives. Oncol Res 2003;14:113-32. (Pubitemid 38166330)
29. Gullbo J, Wickstrom M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour ef ficacy of the melphalan containing prodrug J1. J Drug Target 2003;11:355-63. (Pubitemid 38081339)
30. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8. (Pubitemid 46218843)
31. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-11. (Pubitemid 37494117)
32. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines. A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003;31:271-82. (Pubitemid 36407603)
33. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-95. (Pubitemid 46572539)
34. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67. (Pubitemid 29102494)
35. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104-12. (Pubitemid 26043538)
36. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003;63:7900-6. (Pubitemid 37466725)
37. Jones RB. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res 2002;112:305-22.
38. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90. (Pubitemid 33586303)
39. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002;100:224-9. (Pubitemid 35177451)
40. Kuhn D, Bjorklund C, Magarotto V, Mathews J, Wang M, Baladandayuthapani V, et al. Bortezomib resistance is mediated by increased signaling through the insulin-like growth factor-1/Akt axis [abstract]. In: Proceedings of the 51st ASH Annual Meeting and Exposition Online Program and Abstracts; 2009 Dec 5-8; New Orleans, LA: Ernest N. Morial Convention Center; 2009. p. 114. Abstract nr 2739.
41. Lee CK, Wang S, Huang X, Ryder J, Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett 2010;296:233-40.
42. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
43. Li J, Lee B, Lee AS. Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006;281:7260-70. (Pubitemid 43847494)
44. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73. (Pubitemid 29200799)
45. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKCalpha activation. J Biol Chem 2002;277:7875-81. (Pubitemid 34968236)
46. Laitinen S, Wickstrom M, Fuchs R, Gerwins P, Larsson R, Gullbo J. Aminopeptidase N-activated prodrug melphalan-flufenamide inhibits angiogenesis in vitro and in vivo [abstract]. Mol Cancer Ther; 2011 Nov 12-16; San Francisco, CA: AACR-NCI-EORTC International Conference: Molecular Tragets and Cancer Therapeutics; 2011 (Meeting Abstract Supplement) B6.
47. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003;17:2025-31. (Pubitemid 37322133)